Pearlie K Epling Burnette

Summary

Affiliation: H. Lee Moffitt Cancer Center and Research Institute
Country: USA

Publications

  1. doi request reprint Emerging immunosuppressive drugs in myelodysplastic syndromes
    Pearlie K Epling-Burnette
    H Lee Moffitt Cancer Center and Research Institute, Immunology Department, SRB 23033, 12902 Magnolia Dr, Tampa, FL 33612, USA
    Expert Opin Emerg Drugs 17:519-41. 2012
  2. ncbi request reprint Prevalence and clinical association of clonal T-cell expansions in Myelodysplastic Syndrome
    P K Epling-Burnette
    Immunology Program, H Lee Moffitt Cancer Center, Department of Interdisciplinary Oncology, University of South Florida, Tampa, FL 33612, USA
    Leukemia 21:659-67. 2007
  3. pmc Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors
    Pearlie K Epling-Burnette
    Immunology Program, H Lee Moffitt Cancer Center, MRC 3 West, Tampa, FL 33612, USA
    Blood 109:4816-24. 2007
  4. pmc Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling
    P K Epling-Burnette
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute Immunology Program, James A Haley Veterans Administration Hospital, University of South Florida, Tampa, FL 33612, USA
    Blood 112:4694-8. 2008
  5. doi request reprint Advancements in the molecular pathogenesis of myelodysplastic syndrome
    Pearlie K Epling-Burnette
    H Lee Moffitt Cancer Center Immunology Program, Tampa, Florida 33612, USA
    Curr Opin Hematol 16:70-6. 2009
  6. ncbi request reprint ERK couples chronic survival of NK cells to constitutively activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL)
    Pearlie K Epling-Burnette
    Hematologic Malignancies, Programs from the Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
    Oncogene 23:9220-9. 2004
  7. pmc A critical role for DAP10 and DAP12 in CD8+ T cell-mediated tissue damage in large granular lymphocyte leukemia
    Xianghong Chen
    Immunology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Blood 113:3226-34. 2009
  8. pmc Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib
    Pearlie K Epling-Burnette
    Moffitt Cancer Center, Tampa, FL 33647, USA
    Expert Opin Investig Drugs 19:689-98. 2010

Research Grants

  1. TARGETED DRUG THERAPY FOR LGL LEUKEMIA
    Pearlie K Epling Burnette; Fiscal Year: 2005
  2. Modulation of T cell Homeostasis in Myelodysplastic Syndrome (MDS)
    Pearlie K Epling Burnette; Fiscal Year: 2009
  3. Modulation of T cell Homeostasis in Myelodysplastic Syndrome (MDS)
    Javier Pinilla; Fiscal Year: 2010

Collaborators

  • Sheng Wei
  • Alan F List
  • Dana E Rollison
  • H R Salih
  • L Sokol
  • Pearlie K Epling-Burnette
  • Javier Pinilla
  • Thomas P Loughran
  • P K Epling-Burnette
  • Julie Y Djeu
  • Fanqi Bai
  • Jeffrey S Painter
  • Xianghong Chen
  • Jeffrey A Yoder
  • Junmin Zhou
  • Jianxiang Zou
  • Lynn Moscinski
  • Said Sebti
  • Jessica McDaniel
  • Jinhong Liu
  • Amy Ren
  • Y Ann Chen
  • David A Sallman
  • Todd D Edwards
  • Michelle A Blaskovich
  • Xianhong Chen
  • D Boulware
  • J S Painter
  • David Boulware
  • Matthias Krusch
  • Bin Zhong
  • E Ku
  • Edna Ku
  • F Bai
  • D Vendron
  • R Widen
  • J X Zou
  • Pratima Chaurasia
  • Andrew Hamilton
  • Nancy Olashaw

Detail Information

Publications8

  1. doi request reprint Emerging immunosuppressive drugs in myelodysplastic syndromes
    Pearlie K Epling-Burnette
    H Lee Moffitt Cancer Center and Research Institute, Immunology Department, SRB 23033, 12902 Magnolia Dr, Tampa, FL 33612, USA
    Expert Opin Emerg Drugs 17:519-41. 2012
    ..In early MDS, cytopenias arise or are exacerbated by humoral and cellular immune-mediators that suppress hematopoietic progenitor survival and alter the bone marrow microenvironment...
  2. ncbi request reprint Prevalence and clinical association of clonal T-cell expansions in Myelodysplastic Syndrome
    P K Epling-Burnette
    Immunology Program, H Lee Moffitt Cancer Center, Department of Interdisciplinary Oncology, University of South Florida, Tampa, FL 33612, USA
    Leukemia 21:659-67. 2007
    ..Expanded effector T cell were CD62L negative and expressed the natural killer C-lectin-family receptor NKG2D and CD244 (2B4). We conclude that clonal T-cell expansion is common among all MDS prognostic subgroups...
  3. pmc Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors
    Pearlie K Epling-Burnette
    Immunology Program, H Lee Moffitt Cancer Center, MRC 3 West, Tampa, FL 33612, USA
    Blood 109:4816-24. 2007
    ..Evasion of NK immunosurveillance may have importance for MDS disease progression...
  4. pmc Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling
    P K Epling-Burnette
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute Immunology Program, James A Haley Veterans Administration Hospital, University of South Florida, Tampa, FL 33612, USA
    Blood 112:4694-8. 2008
    ..Coincidental association between PAH and LGL leukemia suggest a causal relationship between the expanded lymphocyte population and these clinical manifestations. This trial is registered at www.ClinicalTrials.gov as NCI 6823...
  5. doi request reprint Advancements in the molecular pathogenesis of myelodysplastic syndrome
    Pearlie K Epling-Burnette
    H Lee Moffitt Cancer Center Immunology Program, Tampa, Florida 33612, USA
    Curr Opin Hematol 16:70-6. 2009
    ..The importance of new advances in myelodysplastic syndrome will be discussed in this review...
  6. ncbi request reprint ERK couples chronic survival of NK cells to constitutively activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL)
    Pearlie K Epling-Burnette
    Hematologic Malignancies, Programs from the Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
    Oncogene 23:9220-9. 2004
    ..These findings suggest that strategies to inhibit this signaling pathway may be useful for the treatment of the NK type of LDGL...
  7. pmc A critical role for DAP10 and DAP12 in CD8+ T cell-mediated tissue damage in large granular lymphocyte leukemia
    Xianghong Chen
    Immunology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Blood 113:3226-34. 2009
    ..Results shown suggest that inhibitors of DAP10 and DAP12 or other proteins involved in this signaling pathway will be attractive therapeutic targets for the treatment of LGLL and other autoimmune diseases and syndromes...
  8. pmc Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib
    Pearlie K Epling-Burnette
    Moffitt Cancer Center, Tampa, FL 33647, USA
    Expert Opin Investig Drugs 19:689-98. 2010
    ..Of all the targeted inhibitors developed, tipifarnib represents one of the few compounds with some activity as a single agent...

Research Grants6

  1. TARGETED DRUG THERAPY FOR LGL LEUKEMIA
    Pearlie K Epling Burnette; Fiscal Year: 2005
    ..Results of these studies should identify important molecular targets for drug development in bone marrow failure syndromes. ..
  2. Modulation of T cell Homeostasis in Myelodysplastic Syndrome (MDS)
    Pearlie K Epling Burnette; Fiscal Year: 2009
    ....
  3. Modulation of T cell Homeostasis in Myelodysplastic Syndrome (MDS)
    Javier Pinilla; Fiscal Year: 2010
    ..Mechanistic studies will aide our understanding of T-cell immunity and improve our ability to utilize this form of immunotherapy and other forms for the treatment of cancer in general. ..